Brainstorm Cell Therapeutics (NASDAQ:BCLI) Coverage Initiated by Analysts at StockNews.com

StockNews.com started coverage on shares of Brainstorm Cell Therapeutics (NASDAQ:BCLIGet Rating) in a report issued on Tuesday. The brokerage issued a hold rating on the biotechnology company’s stock.

Separately, Dawson James reaffirmed a neutral rating on shares of Brainstorm Cell Therapeutics in a report on Wednesday, December 22nd.

Shares of NASDAQ BCLI opened at $3.26 on Tuesday. The company’s fifty day moving average price is $3.23 and its 200 day moving average price is $3.29. Brainstorm Cell Therapeutics has a 1 year low of $2.75 and a 1 year high of $4.46. The company has a market capitalization of $118.94 million, a PE ratio of -4.79 and a beta of -0.04.

Brainstorm Cell Therapeutics (NASDAQ:BCLIGet Rating) last announced its quarterly earnings results on Monday, March 28th. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.20) by $0.03. During the same quarter in the previous year, the company earned ($0.37) EPS. As a group, equities analysts predict that Brainstorm Cell Therapeutics will post -0.87 earnings per share for the current fiscal year.

A number of institutional investors and hedge funds have recently bought and sold shares of BCLI. GSA Capital Partners LLP lifted its holdings in Brainstorm Cell Therapeutics by 185.6% during the third quarter. GSA Capital Partners LLP now owns 172,056 shares of the biotechnology company’s stock valued at $568,000 after purchasing an additional 111,818 shares in the last quarter. Weaver Consulting Group lifted its stake in shares of Brainstorm Cell Therapeutics by 201.9% in the fourth quarter. Weaver Consulting Group now owns 155,500 shares of the biotechnology company’s stock worth $622,000 after buying an additional 104,000 shares in the last quarter. Abner Herrman & Brock LLC lifted its stake in shares of Brainstorm Cell Therapeutics by 13.7% in the first quarter. Abner Herrman & Brock LLC now owns 265,000 shares of the biotechnology company’s stock worth $890,000 after buying an additional 32,000 shares in the last quarter. Morgan Stanley lifted its stake in shares of Brainstorm Cell Therapeutics by 42.3% in the second quarter. Morgan Stanley now owns 53,685 shares of the biotechnology company’s stock worth $205,000 after buying an additional 15,964 shares in the last quarter. Finally, S.C. Financial Services Inc. purchased a new position in shares of Brainstorm Cell Therapeutics in the fourth quarter worth about $52,000. 14.47% of the stock is currently owned by institutional investors and hedge funds.

About Brainstorm Cell Therapeutics (Get Rating)

Brainstorm Cell Therapeutics, Inc operates as a biotechnology company, which develops and commercializes adult stem cell therapeutic products. It focuses on utilizing the patients own bone marrow stem cells to generate neuron-like cells that may provide an effective treatment initially for amyotrophic lateral sclerosis, Parkinson’s disease, multiple sclerosis and spinal cord injury.

Featured Stories

Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.